TG Therapeutics, Inc. (NASDAQ:TGTX) has analysts on the Bullish side this week.

February 15, 2018 - By Adrian Mccoy

 TG Therapeutics, Inc. (NASDAQ:TGTX) has analysts on the Bullish side this week.
Investors sentiment decreased to 1.21 in 2017 Q3. Its down 1.07, from 2.28 in 2017Q2. It fall, as 11 investors sold TG Therapeutics, Inc. shares while 22 reduced holdings. 11 funds opened positions while 29 raised stakes. 35.13 million shares or 3.60% more from 33.91 million shares in 2017Q2 were reported.
Great West Life Assurance Co Can, a Manitoba – Canada-based fund reported 10,839 shares. Schwab Charles Mgmt reported 243,485 shares. Sei holds 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX) for 44 shares. Hikari Power reported 160,000 shares or 0.25% of all its holdings. Virtu Financial Llc owns 20,112 shares. Goldman Sachs Grp has 21,727 shares. Kennedy Cap has 421,229 shares for 0.09% of their portfolio. Thompson Davis And Co accumulated 3,032 shares or 0.06% of the stock. Citigroup reported 96,215 shares stake. Geode Capital Mgmt Lc owns 453,571 shares. New York State Common Retirement Fund accumulated 102,853 shares or 0% of the stock. Morgan Stanley owns 102,488 shares. Grp One Trading Lp reported 0.01% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). The California-based Fincl Advisers Ltd Liability Com has invested 0.01% in TG Therapeutics, Inc. (NASDAQ:TGTX). American Gp invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX).

Since December 29, 2017, it had 0 insider purchases, and 1 sale for $272,051 activity.

TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 19 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Buy” rating by B. Riley & Co on Friday, December 1. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by FBR Capital on Thursday, June 15. On Monday, December 11 the stock rating was maintained by FBR Capital with “Buy”. The firm earned “Buy” rating on Wednesday, January 17 by FBR Capital. The stock has “Hold” rating by Zacks on Wednesday, August 12. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Friday, February 2 by FBR Capital. H.C. Wainwright reinitiated the shares of TGTX in report on Tuesday, November 14 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Monday, December 11. H.C. Wainwright reinitiated the stock with “Buy” rating in Wednesday, August 12 report. The company was initiated on Tuesday, December 1 by FBR Capital. Below is a list of TG Therapeutics, Inc. (NASDAQ:TGTX) latest ratings and price target changes.

02/02/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
17/01/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
12/12/2017 Broker: Raymond James Rating: Buy
11/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $33.0 Maintain
11/12/2017 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
01/12/2017 Broker: B. Riley & Co Rating: Buy New Target: $21.5 Maintain
30/11/2017 Broker: FBR Capital Rating: Buy New Target: $21.5
14/11/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $33 Reinitiate
18/10/2017 Broker: SunTrust Rating: Buy

The stock increased 0.80% or $0.1 during the last trading session, reaching $12.55. About 935,286 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 60.54% since February 15, 2017 and is uptrending. It has outperformed by 43.84% the S&P500.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $886.69 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

More recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: which released: “TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study …” on February 02, 2018. Also published the news titled: “TG Therapeutics: Further Appreciation In 2018 Likely” on February 06, 2018.‘s news article titled: “TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual …” with publication date: January 24, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.